• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Supartz

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Supartz

  • Profile

Profile

Contact Information

Contact: Bioventus
Website: http://www.oakneepainrelief.com/supartz_fx/

Currently Enrolling Trials

    Show More

    General Information

    Supartz is a joint fluid therapy approved for the treatment of osteoarthritis (OA) in the knee in patients who have responded poorly to non-pharmacologic therapy and simple analgesics. This drug is a clear, viscous liquid that is injected into the knee joint. It is designed to provide long-term pain relief by supplementing the body's natural synovial fluid, which is degraded due to OA.

    Mechanism of Action

    Supartz (sodium hyaluronate) is similar to the body's natural synovial fluid, which helps joints function by acting as a lubricant and shock absorber. Supartz is purified to remove all detectable DNA, protein and endotoxins. The clear liquid is injected directly into the knee joint.

    Side Effects

    Adverse events associated with the use of sodium hyaluronate may include (but are not limited to) the following:

    • joint pain
    • injection site reaction
    • diarrhea
    • headache
    • nausea

    Dosing/Administration

    Supartz is administered by intra-articular injection once a week for a total of five injections.

    There are an estimated 20 million individuals suffering from OA in the United States. A person's joints, most commonly the knees and hips, are affected by degeneration that causes them to be and painfully inflamed.

    Clinical Trial Results

    The effectiveness of Supartz was evaluated in 18 clinical studies involving more than 10,700 patients suffering from OA in the knee, including patients of a Japanese post-market survey. Since its introduction in Japan in 1987, over 100 million successful Supartz injections have been administered.

    Approval Date: 2001-01-01
    Company Name: Smith & Nephew Orthopaedics
    Back to Listings

    Upcoming Events

    • 24May

      Powering an Effective Oversight Strategy with Clinical and Operational Insights

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing